The manager’s view: Outlook favours MUT’s approach
In the last two months of 2020, the arrival of viable vaccines, combined with Joe Biden’s election to the US presidency and the finalisation of a Brexit deal, led to a surge of optimism about the economic outlook in the UK, and around the world. Investors became more positive about the prospects of companies in economically sensitive sectors such as banks, industrials and oil and gas, triggering a rotation into these cyclical and value stocks. This rotation, which came at the expense of the high-value technology and other growth stocks that have made significant gains since the onset of the pandemic, continued during the first quarter of 2021.
However, Murray Income Trust’s manager, Charlie Luke, believes the rotation will prove to be a short-lived phenomenon. He maintains that the uptick in the prices of these cyclical and value companies caused specifically by the vaccine-related improvement in the economic outlook ‘can only happen once, and it has happened’. And even if the rotation does continue, it will not alter Luke’s investment approach or his focus on quality companies. He argues that many of the companies that benefited most from this shift in market sentiment were low-quality companies whose capacity to survive the pandemic had, up until late 2020, been in question. ‘These are poor quality companies and have no place in a portfolio of quality companies like ours’ Luke says.
Despite the good news on the vaccine front, in Luke’s view the trajectory of the economic recovery remains uncertain in many places. Coronavirus case numbers remain high in India, Latin America and some European countries, and vaccine rollouts have been slow in most countries, hindering plans to re-open borders and lift lockdowns. However, the manager believes the UK outlook is clearer, thanks to the success of the government’s vaccination program. He expects a sharp recovery over the remainder of this year, to be followed by a long period of low interest rates, modest growth, high levels of corporate indebtedness and consequent pressure on company profits. Unlike many investors and commentators, Luke does not expect inflationary pressures to take hold. ‘We believe that the forces that have weighed down on inflation for the past 30 years will still be present, including a significant output gap, the limited power of labour, price transparency and demographic factors.’
In these less than favourable circumstances, MUT’s manager believes that companies with attractive yields, sound growth prospects and strong balance sheets are likely to be highly prized. ‘Therefore, it seems eminently sensible to maintain our careful and measured approach to investing in high quality companies that should be able to thrive in this challenging environment and emerge over time in a stronger competitive position’ he reasons.
Luke has added several such companies to the portfolio in recent months, including Moonpig, a greeting card and gifting company; Electrocomponents, an electrical product retailer; and the homebuilder Vistry. Luke believes Vistry’s share price does not reflect the significant growth potential of its Partnerships business, which collaborates with local authorities and public housing associations on regeneration projects. One Savings Bank, a buy-to-let lender, is another new addition to the portfolio, along with Stenprop, which owns UK multi-let industrial property and offers an attractive dividend yield, at an appealing valuation.
The manager has also added to several existing positions including pharmaceutical and vaccine producer Astra Zeneca (MUT’s largest position, Exhibit 1); Coca-Cola Hellenic, a drinks company; Sanne, a fund administrator; and Safestore, which owns and operates self-storage units, mainly in the UK and France. Luke likes this company because of its attractive defensive attributes and its scope to expand. He has also topped up exposure to Direct Line, a personal and commercial insurance provider, due to its attractive dividend yield and resilient earnings stream.
Exhibit 1: Top 10 holdings (as at 31 March 2021)
Company |
Country |
Industry |
Portfolio weight % |
31 March 2021 |
31 March 2020* |
AstraZeneca |
UK |
Healthcare |
4.7 |
4.0 |
Diageo |
UK |
Consumer goods |
4.5 |
3.7 |
Rio Tinto |
UK |
Materials |
3.8 |
3.1 |
BHP |
UK |
Materials |
3.8 |
N/A |
Unilever |
UK |
Consumer goods |
3.5 |
3.2 |
RELX |
UK |
Media |
3.5 |
3.5 |
Standard Chartered |
UK |
Financials |
3.0 |
N/A |
Close Brothers |
UK |
Financials |
2.9 |
N/A |
National Grid |
UK |
Utilities |
2.7 |
3.1 |
SSE |
UK |
Utilities |
2.7 |
N/A |
Top 10 (% of portfolio) |
|
|
35.1 |
33.4 |
Source: Murray Income Trust, Edison Investment Research, Bloomberg, Morningstar. Note: *N/A where not in end-March 2020 top 10.
Luke has also trimmed some positions, taking profits on holdings that have done so well that valuations have begun to look less attractive. These partial sales have included pharmaceutical company Roche, software provider Aveva and LondonMetric, a diversified REIT. In addition, the manager disposed of the trust’s entire position in British American Tobacco, a decision motivated by environmental, social and corporate governance (ESG) considerations; owning a tobacco company is not consistent with the trust’s ESG principles. The company could also be vulnerable to a general re-rating as other investors adopt a more proactive stance on companies in this industry. Luke also disposed of a position in Standard Life UK Smaller Companies Trust. Its performance has been ‘fantastic’ he says, but he is now buying these mid-cap companies directly.
Exhibit 2: MUT’s overseas holdings as at 31 March 2021
Company |
Country |
Sector |
% of portfolio end March 2021 |
Total |
France |
Oil & gas producers |
2.4 |
Coca-Cola HBC |
Switzerland |
Beverages |
2.3 |
Nestlé |
Switzerland |
Food producers |
1.6 |
Telenor |
Norway |
Mobile telecommunications |
1.4 |
Novo-Nordisk |
Denmark |
Pharmaceuticals & biotechnology |
1.2 |
Kone |
Finland |
Industrial engineering |
1.1 |
Microsoft |
USA |
Software & computer services |
1.0 |
VAT Group |
Switzerland |
Industrial engineering |
1.0 |
Roche Holdings |
Switzerland |
Pharmaceuticals & biotechnology |
0.7 |
Mowi |
Norway |
Industrial engineering |
0.7 |
Source: Murray Income Trust, Edison Investment Research
Exhibit 3: Portfolio sector exposure vs benchmark (% unless stated)
|
Portfolio end- March 2021 |
Portfolio end- March 2020 |
Change (pp) |
Index weight |
Active weight vs index (pp) |
Trust weight/ index weight (x) |
Financials |
23.3 |
19.1 |
4.2 |
26.4 |
(3.1) |
0.9 |
Consumer goods |
17.0 |
17.0 |
0.0 |
15.5 |
1.5 |
1.1 |
Healthcare |
11.6 |
15.8 |
(4.2) |
8.4 |
3.2 |
1.4 |
Industrials |
11.6 |
11.7 |
(0.1) |
12.7 |
(1.1) |
0.9 |
Basic materials |
11.0 |
8.9 |
2.1 |
9.4 |
1.6 |
1.2 |
Consumer services |
9.7 |
9.3 |
0.4 |
12.9 |
(3.2) |
0.8 |
Utilities |
5.5 |
5.5 |
(0.1) |
3.0 |
2.5 |
1.8 |
Oil & gas |
3.9 |
4.6 |
(0.6) |
7.6 |
(3.7) |
0.5 |
Technology |
3.7 |
5.0 |
(1.3) |
1.8 |
1.9 |
2.1 |
Telecommunications |
2.5 |
3.1 |
(0.5) |
2.3 |
0.2 |
1.1 |
|
100.0 |
100.0 |
|
100.0 |
|
|
Source: Murray Income Trust, Edison Investment Research
These transactions have resulted in the number of portfolio holdings rising to 61 stocks at end March, up from 56 in October 2020. The portfolio’s non-UK holdings remained unchanged as at end March 2021, from June 2020 (Exhibit 2), although trims to some of the 10 positions reduced the percentage of the portfolio’s non-UK holdings to 13.4%, compared to 16.1% in mid-2020. With the exceptions of Microsoft and Total, these foreign holdings are listed in Switzerland and the Nordic countries, although the manager has indicated that he is considering adding a Taiwanese name to the list, which would be the portfolio’s first Asian name. MUT currently has 12 short call option positions, which comprise a total of 3% of the portfolio, so each option represents a call on only a very small portion of the portfolio. The calls are written against companies including Close Brothers bank (a top 10 holding), software provider Aveva, paper products supplier Mondi, Countryside Properties, and two Swiss companies, Roche and engineering company VAT Group. Annualised portfolio turnover stood at 21% at end March, close to the five-year average of 20%. At the end of April 2021, the portfolio’s forward P/E was 16.8x, compared to 14.2x for the UK market, which Luke argues ‘is a small price to pay for a higher quality portfolio’.